The estimated Net Worth of Virginia Ewoltosz Walter S ... is at least $187 million dollars as of 9 May 2017. Virginia S owns over 19,524 units of Simulations Plus stock worth over $187,129,079 and over the last 11 years Virginia sold SLP stock worth over $243,074.
Virginia has made over 1 trades of the Simulations Plus stock since 2017, according to the Form 4 filled with the SEC. Most recently Virginia sold 19,524 units of SLP stock worth $243,074 on 9 May 2017.
The largest trade Virginia's ever made was selling 19,524 units of Simulations Plus stock on 9 May 2017 worth over $243,074. On average, Virginia trades about 6,508 units every 0 days since 2013. As of 9 May 2017 Virginia still owns at least 5,703,416 units of Simulations Plus stock.
You can see the complete history of Virginia S stock trades at the bottom of the page.
Virginia's mailing address filed with the SEC is 42505 10TH STREET WEST42505 10TH STREET WEST, , LANCASTERLANCASTER, CACA, 9353493534.
Over the last 20 years, insiders at Simulations Plus have traded over $70,055,940 worth of Simulations Plus stock and bought 24,000 units worth $1,395,840 . The most active insiders traders include Walter Swoltosz Virginia E ..., Walter S Woltosz et Momoko A Beran. On average, Simulations Plus executives and independent directors trade stock every 37 days with the average trade being worth of $571,025. The most recent stock trade was executed by Jill Fiedler Kelly on 9 September 2024, trading 2,250 units of SLP stock currently worth $21,848.
simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res
Simulations Plus executives and other stock owners filed with the SEC include: